View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Insight Enterprises, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 April 2025 in which we reassessed the appropriateness of the ratings in the co...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings affirms FIS's Baa2 senior unsecured rating; outlook st...

Moody's Ratings (Moody's) affirmed Fidelity National Information Services, Inc.'s ("FIS") senior unsecured notes rating of Baa2, senior unsecured shelf rating of (P)Baa2 and P-2 commercial paper rating. The rating outlook is stable. The ratings action follows FIS's announcement that it plans to ac...

 PRESS RELEASE

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme...

 PRESS RELEASE

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 ...

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3...

 PRESS RELEASE

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock to nine (9) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Franklin Financial Services Corp: 1 director

A director at Franklin Financial Services Corp bought 6,756 shares at 37.000USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Testing Initial Support In last week's 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, and that if the S&P 500 remains below 6100 and 6150 resistances, do not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers (though we need 5...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Ca...

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in one-on-one in...

Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico

Markel Group Inc: 2 directors

A director at Markel Group Inc sold 2,200 shares at 1,864.760USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

Vera Therapeutics Provides Business Update and Reports Fourth Quarter ...

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgAN BRIS...

 PRESS RELEASE

Insight to Present at Raymond James 46th Annual Institutional Investor...

CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”) today announced that it is scheduled to participate in the following upcoming investor conference: Raymond James 46th Annual Institutional Investors Conference March 4, 2025, 8:05 AM ET Participants: James Morgado, CFO The Insight presentation will be broadcast live over the Internet at where you can also view other recent webcasts, downloadable slide presentations and other investor information. About Insight Insight Enterprises is a leading Solutions Integrator that helps clients solve techno...

Ringcentral Inc: 2 directors

Two Directors at Ringcentral Inc sold/sold after exercising options 247,740 shares at between 28.558USD and 28.692USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...

Wedbush Research
  • Wedbush Research
SGI SOMNIGROUP INTERNATIONAL INC
W WAYFAIR INC.
DPZ DOMINO'S PIZZA INC.
SHAK SHAKE SHACK INC. CLASS A
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RNG RINGCENTRAL INC. CLASS A
QLYS QUALYS INC.
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
LOW LOWE'S COMPANIES INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
GME GAMESTOP CORP. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
AXTI AXT INC.
INOD INNODATA
BJRI BJ'S RESTAURANTS INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
NICE NICE LTD
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
SMCI SUPER MICRO COMPUTER
ACET INC.
FUBO ADICET BIO INC
U FUBOTV
DASH UNITY SOFTWARE
ABNB DOORDASH
CGEM AIRBNB INC. CLASS A
STX CULLINAN ONCOLOGY INC
ALIT SEAGATE TECHNOLOGY HLDGS PLC
TTD FOLEY TRASIMENE ACQUISITION CORP
RIVN THE TRADE DESK
GFS INC.
ARTV RIVIAN AUTOMOTIVE INC
CAVA GLOBALFOUNDRIES INC
SYRE ARTIVA BIOTHERAPEUTICS INC
AVTX CAVA GROUP INC
SPYRE THERAPEUTICS INC.
AVALO THERAPEUTICS INC
Daniel Ives ... (+3)
  • Daniel Ives
  • Sam Brandeis
  • Steven Wahrhaftig
 PRESS RELEASE

Insight Flex for Devices Brings Automated Simplicity to Enterprise Dev...

CHANDLER, Ariz.--(BUSINESS WIRE)-- (NASDAQ: NSIT) today unveiled its enhanced (Flex) program, offering organizations cost-saving and simplified Device-as-a-Service (DaaS) solutions. Flex improves employee experience (EX) by getting the right devices to the right users when they need them to minimize downtime and increase productivity. With automation, proactive communications, a simplified e-commerce experience, and near-real-time intelligent data, organizations gain visibility for better device management. This press release features multimedia. View the full release here: Amid economic un...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch